title: A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch.
abstract: BACKGROUND
  Monoamine oxidase B (MAO-B) activity is reduced in smokers. A MAO-B inhibitor alone or co-administered with nicotine may mimic the effects of smoking and be a candidate drug for smoking cessation.
  
  
  OBJECTIVE
  This study aims to determine the efficacy and safety of EVT302, a selective reversible MAO-B inhibitor, alone and on top of nicotine patch (NP) in smoking cessation.
  
  
  METHODS
  This was a randomised, double blind, placebo-controlled phase II, multicentre trial. Smokers (≥10 cigarettes/day) received either EVT302 (N = 145) or placebo (N = 145), or EVT302 (N = 61) or placebo (N = 61) on top of open label NP 21 mg/day for 8 weeks. The main comparison was between EVT302 and placebo without NP. The primary outcome measure was end-of-treatment 4-week continuous abstinence rate (CAR).
  
  
  METHODS
  point prevalence abstinence rate, saliva cotinine concentrations in the groups without NP, urge to smoke, nicotine withdrawal symptoms and assessment of subjective effects of cigarettes.
  
  
  RESULTS
  The 4-week CAR was 15.2 % in the placebo, 17.2 % in the EVT302, 26.8 % in the NP + placebo and 32.8 % in the NP + EVT302 groups, respectively. There was no difference between EVT302 and placebo either alone (adjusted OR: 1.45, 95 % CI: 0.65-3.26) or when co-administered with NP. No statistically significant difference occurred for the secondary outcome measures.
  
  
  CONCLUSIONS
  The selective, reversible MAO-B inhibitor EVT302 was not superior to placebo in helping smokers quit, in line with data with selegiline and confirms that MAO-B inhibitors are not effective in smoking cessation. Co-administration of NP does not provide a supplementary benefit.
authors.affiliation: Département de Pharmacologie, Hôpital Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris-Faculté de médicine, Université P. & M. Curie-INSERM U894, 47, bd de l'Hôpital, 75013 Paris, France. ivan.berlin@psl.aphp.fr
authors.forename: Ivan
authors.initials: I
authors.lastname: Berlin
authors.forename: Ian M
authors.initials: IM
authors.lastname: Hunneyball
authors.forename: Doris
authors.initials: D
authors.lastname: Greiling
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Jones
authors.forename: Hermann
authors.initials: H
authors.lastname: Fuder
authors.forename: Hans-Detlev
authors.initials: HD
authors.lastname: Stahl
mesh_terms: D000328:Adult; D003367:Cotinine / Q000378:metabolism; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012463:Saliva / Q000737:chemistry; D016540:Smoking Cessation / Q000379:methods*; D061485:Tobacco Use Cessation Devices; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D008996:Monoamine Oxidase Inhibitors; D003367:Cotinine